Generic Development of Topical Dermatologic Products, Part II: Quality by Design for Topical Semisolid Products
Journal Title: The AAPS Journal - Year 2013, Vol 15, Issue 3
Abstract
The emergence of quality by design as a relatively new systematic science and risk-based approach has added a new dimension to pharmaceutical development and manufacturing. This review attempts to discuss the quality by design elements and concepts applied for topical semisolid products. Quality by design begins with defining a quality target product profile as well as critical quality attributes. Subsequently, this is followed by risk identification/risk analysis/risk evaluation to recognize critical material attributes and critical process parameters, in conjunction with design of experiments or other appropriate methods to establish control strategies for the drug product. Several design-of-experiment examples are included as practical strategies for the development and optimization of formulation and process for topical drug products.
Authors and Affiliations
Rong-Kun Chang, Andre Raw, Robert Lionberger, Lawrence Yu
Keywords
Related Articles
- EP ID EP681122
- DOI 10.1208/s12248-013-9472-8
- Views 53
- Downloads 0
Meeting Report: Applied Biopharmaceutics and Quality by Design for Dissolution/Release Specification Setting: Product Quality for Patient Benefit
The online version of this article (doi:10.1208/s12248-010-9206-0) contains supplementary material, which is available to authorized users.
Pre-Existing Biotherapeutic-Reactive Antibodies: Survey Results Within the American Association of Pharmaceutical Scientists
The immunogenicity profile of a biotherapeutic is determined by a multitude of product and patient-related risk factors that can influence the observed incidence and clinical consequences of immunogenicity. Pre-existing...
Mu opioid receptor regulation and opiate responsiveness
Opiate drugs such as morphine are well known for their ability to produce potent analgesia as well as such unwanted side effects as tolerance, physical dependence, respiratory suppression and constipation. Opiates act at...
Population analysis of the pharmacokinetics and pharmacodynamics of RWJ-270201 (BCX-1812) in treating experimental influenza A and B virus in healthy volunteers
Our objective was to assess the pharmacokinetics and pharmacodynamics of RWJ-270201 (BCX-1812), an oral neuraminidase inibitor for the treatment of influenza A and B virus in healthy volunteers.
2-Arachidonoylglycerol (2-AG) membrane transport: History and outlook
Only a few studies have addressed the transport of 2-arachidonoylglycerol (2-AG), a naturally occurring agonist for cannabinoid receptors. Based upon saturation kinetics, these early reports have proposed that 2-AG enter...